Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment.

Alopecia areata JAK inhibitors baricitinib infectious events, real-life study upadacitinib

Journal

Expert opinion on drug safety
ISSN: 1744-764X
Titre abrégé: Expert Opin Drug Saf
Pays: England
ID NLM: 101163027

Informations de publication

Date de publication:
08 May 2024
Historique:
medline: 8 5 2024
pubmed: 8 5 2024
entrez: 8 5 2024
Statut: aheadofprint

Résumé

Alopecia areata (AA) is a non-scarring disorder characterized by hair loss that greatly affects patients' quality of life and has a chronic, recurring course. This disease is marked by an inflammatory process, mainly on an autoimmune basis primarily regulated by Janus kinase (JAK). We conducted a retrospective study evaluating the safety of JAKi in a real-world setting in 91 AA patients, with a specific focus on the assessment of infectious events. Overall, 34 infectious events were observed in 28 patients (30.8%), among them 17 patients (60.7%) suspended treatment with JAKi until the infection was clinically resolved. Only in one case the infectious event led to a permanent discontinuation of the treatment. The data we observed in the study are consistent with results reported in clinical trials. It can be stated that, during treatment with JAKi in AA patients, infectious events may occur, but in most cases these events are easily manageable and do not result in permanent discontinuation of the drug.

Sections du résumé

BACKGROUND UNASSIGNED
Alopecia areata (AA) is a non-scarring disorder characterized by hair loss that greatly affects patients' quality of life and has a chronic, recurring course. This disease is marked by an inflammatory process, mainly on an autoimmune basis primarily regulated by Janus kinase (JAK).
RESEARCH DESIGN AND METHODS UNASSIGNED
We conducted a retrospective study evaluating the safety of JAKi in a real-world setting in 91 AA patients, with a specific focus on the assessment of infectious events.
RESULTS UNASSIGNED
Overall, 34 infectious events were observed in 28 patients (30.8%), among them 17 patients (60.7%) suspended treatment with JAKi until the infection was clinically resolved. Only in one case the infectious event led to a permanent discontinuation of the treatment. The data we observed in the study are consistent with results reported in clinical trials.
CONCLUSION UNASSIGNED
It can be stated that, during treatment with JAKi in AA patients, infectious events may occur, but in most cases these events are easily manageable and do not result in permanent discontinuation of the drug.

Identifiants

DOI: 10.1080/14740338.2024.2348571 PMID: 38717372
pubmed: 38717372
doi: 10.1080/14740338.2024.2348571
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-5

Auteurs

Giacomo Caldarola (G)

UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.

Lorenzo Maria Pinto (LM)

UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.

Francesco Bellinato (F)

Department of Medicine, Section of Dermatology, University of Verona, Verona, Italy.

Nicoletta Bernardini (N)

Dermatology Unit "Daniele Innocenzi" ASL LATINA, Sapienza University of Rome, Rome, Italy.

Elena Campione (E)

UOSD di Dermatologia, Azienda Ospedaliera Universitaria "Policlinico Tor Vergata", Rome, Italy.
Dipartimento di Medicina dei Sistemi, Università di Roma, Rome, Italy.

Andrea Chiricozzi (A)

UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
ORCID: 0000-0002-6739-0387

Laura Colonna (L)

Dermatology Unit, IDI-IRCCS, Rome, Italy.

Clara De Simone (C)

UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.

Laura Diluvio (L)

UOSD di Dermatologia, Azienda Ospedaliera Universitaria "Policlinico Tor Vergata", Rome, Italy.
Dipartimento di Medicina dei Sistemi, Università di Roma, Rome, Italy.

Paolo Gisondi (P)

Department of Medicine, Section of Dermatology, University of Verona, Verona, Italy.
ORCID: 0000-0002-1777-9001

Enrico Matteini (E)

UOSD di Dermatologia, Azienda Ospedaliera Universitaria "Policlinico Tor Vergata", Rome, Italy.

Eleonora Tomassetti (E)

UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.

Ersilia Tolino (E)

Dermatology Unit "Daniele Innocenzi" ASL LATINA, Sapienza University of Rome, Rome, Italy.

Luca Bianchi (L)

UOSD di Dermatologia, Azienda Ospedaliera Universitaria "Policlinico Tor Vergata", Rome, Italy.
Dipartimento di Medicina dei Sistemi, Università di Roma, Rome, Italy.

Ketty Peris (K)

UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.

Classifications MeSH